ESR1 and breast cancer: For example, the ELAINE-1 trial randomized women with locally advanced/metastatic ER+/HER2− BC, an ESR1 mutation, and disease progression on AI and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, to receive lasofoxifene vs. fulvestrant.